3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Thyroid Cancer, Papillary
1
Precancerous Conditions
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Cervical Neoplasia
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
4
Iodine-131
4
Sunitinib
3
dabrafenib
2
Trastuzumab
2
Thyrotropin Alfa
2
Thyroidectomy
2
Surgical Procedures, Operative
2
Gefitinib
2
Fluorodeoxyglucose F18
2
Bortezomib
2
AZD 6244
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trametinib
1
tipifarnib
1
tanespimycin
1
sargramostim
1
romidepsin
1
pralsetinib
1
pembrolizumab
1
pazopanib
1
motesanib diphosphate
1
mercaptoundecahydrododecaborate
1
lenvatinib
1
delta 24-sterol reductase
1
copanlisib
1
cediranib
1
aldesleukin
1
aflibercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Thyroid Cancer, Papillary
×
Spectrum Analysis
×
Clear all
NCT03470259
2024-04-16
TARGET
University Medical Center Groningen
Phase 1
Completed
19 enrolled